Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
11-valent HPV vaccine immunogenicity in Chinese women
NCT04436133Phase 2Completed
- Sponsor
- Serum Institute of India
- Start
- Jun 2020
- Primary completion
- Mar 2022
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of 11-valent recombinant human papilloma virus vaccine in human papillomavirus infection, Cervical Cancer (CC), sponsored by Serum Institute of India. Started Jun 2020; status: completed.
02
Drugs
11-valent recombinant human papilloma virus vaccine
03
Conditions
human papillomavirus infectionCervical Cancer (CC)
Beyond the preview
Go deeper on NCT04436133.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04436133.